Latest news with #Hamelin
Mint
22-07-2025
- Entertainment
- Mint
Baby Grok: A chatbot that'll need more than a nanny
Decades ago, debates raged over the exposure of children to external influences like advertising. The internet turned the idea of shielding kids into a lost cause, but Elon Musk's proposed launch of a 'kid-friendly" AI chatbot called Baby Grok should revive concerns. The name hints of an inbuilt nanny to keep chats age-appropriate. Also read: The parents letting their kids talk to a mental-health chatbot Yet, as an AI brand, xAI's Grok has already distinguished itself with scandalous responses and uncivil comments. This chatbot's boorish behaviour has spawned memes and amused many, but also left observers aghast at xAI's anything-goes approach to chatbot training. While it may conform with Musk's absolutist position on free speech, it also suggests a dismal likelihood that parents would be glad to have their kids engage any chatbot from xAI, regardless of how the company pitches Baby Grok. Also read: Superhuman AI may be the next Pied Piper of Hamelin for our kids If Musk's strategic intent is to 'catch them young", then that's all the more reason to put this project to scrutiny. If Musk's declaration is just a decoy, plausibly meant to defend Grok by insinuating that adult chats need no filters, then we might have less to worry about. Also read: Superhuman AI may be the next Pied Piper of Hamelin for our kids Either way, demanding age gates for chatbot access may be worth a try.
Yahoo
12-05-2025
- Business
- Yahoo
New Statistics Canada Data Reinforces Life Sciences as an Economic Engine
Innovative Pharmaceutical Industry Contributed $18.4 Billion to the Canadian Economy in 2022 OTTAWA, ON, May 12, 2025 /CNW/ - New data released today by Statistics Canada confirms that Canada's innovative pharmaceutical industry is more than a contributor to health, it is a driver of national economic growth and resilience. The industry contributed $18.4 billion in 2022 in total economic activity, marking a nearly 15% increase over 2021. It also invested up to $3.2 billion in R&D and supported more than 110,000 full-time jobs across the country—an almost 8% increase in jobs over the previous year. These findings underscore the industry's significant role in shaping Canada's innovation ecosystem, building research capacity, and driving long-term prosperity. "Canada's life sciences are an economic engine. In an increasingly complex and volatile global economy, that engine needs to be firing on all cylinders," said Bettina Hamelin, President of Innovative Medicines Canada. "Canada's pharmaceutical innovators are helping deliver both life-changing treatments and the kind of growth that strengthens our economic resilience as a country." This new data reveals an R&D-to-sales ratio of up to 11%, reflecting the industry's strong commitment to reinvest in Canadian science, talent, and infrastructure. With more than 3,200 clinical trials, world-class academic institutions, groundbreaking AI capabilities, and a thriving biotech pipeline, Canada is well-positioned to lead. But continued growth of a competitive Canadian business environment depends on ambitious and forwardlooking policies, smart investments, and sustained public-private collaboration. "Canada's leadership in clinical trials is something to be proud of—and something we must protect and amplify," added Hamelin. "It's a competitive advantage that creates jobs, fuels innovation, and delivers real health benefits to Canadians." About Innovative Medicines Canada Innovative Medicines Canada (IMC) is the national association representing Canada's innovative pharmaceutical industry. The industry proudly supports more than 110,000 jobs, contributes a total of $18.4 billion to the economy, sponsors the majority of clinical trials in Canada, and invests close to $3.2 billion in research and development each year. IMC advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians. The association and its members are committed to being solutions-oriented partners in Canada's healthcare system and have contributed more than $30 million towards applied health systems research through the Health Research Foundation (HRF). Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner. SOURCE Innovative Medicines Canada View original content to download multimedia:
Cision Canada
12-05-2025
- Business
- Cision Canada
New Statistics Canada Data Reinforces Life Sciences as an Economic Engine
Innovative Pharmaceutical Industry Contributed $18.4 Billion to the Canadian Economy in 2022 OTTAWA, ON, May 12, 2025 /CNW/ - New data released today by Statistics Canada confirms that Canada's innovative pharmaceutical industry is more than a contributor to health, it is a driver of national economic growth and resilience. The industry contributed $18.4 billion in 2022 in total economic activity, marking a nearly 15% increase over 2021. It also invested up to $3.2 billion in R&D and supported more than 110,000 full-time jobs across the country—an almost 8% increase in jobs over the previous year. These findings underscore the industry's significant role in shaping Canada's innovation ecosystem, building research capacity, and driving long-term prosperity. "Canada's life sciences are an economic engine. In an increasingly complex and volatile global economy, that engine needs to be firing on all cylinders," said Bettina Hamelin, President of Innovative Medicines Canada. "Canada's pharmaceutical innovators are helping deliver both life-changing treatments and the kind of growth that strengthens our economic resilience as a country." This new data reveals an R&D-to-sales ratio of up to 11%, reflecting the industry's strong commitment to reinvest in Canadian science, talent, and infrastructure. With more than 3,200 clinical trials, world-class academic institutions, groundbreaking AI capabilities, and a thriving biotech pipeline, Canada is well-positioned to lead. But continued growth of a competitive Canadian business environment depends on ambitious and forwardlooking policies, smart investments, and sustained public-private collaboration. "Canada's leadership in clinical trials is something to be proud of—and something we must protect and amplify," added Hamelin. "It's a competitive advantage that creates jobs, fuels innovation, and delivers real health benefits to Canadians." About Innovative Medicines Canada Innovative Medicines Canada (IMC) is the national association representing Canada's innovative pharmaceutical industry. The industry proudly supports more than 110,000 jobs, contributes a total of $18.4 billion to the economy, sponsors the majority of clinical trials in Canada, and invests close to $3.2 billion in research and development each year. IMC advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians. The association and its members are committed to being solutions-oriented partners in Canada's healthcare system and have contributed more than $30 million towards applied health systems research through the Health Research Foundation (HRF). Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
Yahoo
07-04-2025
- Business
- Yahoo
Hamelin Gold to accelerate exploration at WA gold projects with $1.68m placement
Australian Securities Exchange (ASX)-listed gold exploration company Hamelin Gold has secured firm commitments from investors to raise approximately A$2.8m ($1.68m) before costs, with shares priced at A$0.07 each, to accelerate gold exploration in Western Australia (WA). This funding includes an investment of around $815,000 from Gold Fields, a major shareholder in Hamelin, increasing its stake to approximately 17.7%. The placement also sees commitments from Hamelin's directors for roughly $100,000 in shares. The net proceeds from the placement will primarily finance exploration activities at the company's 100% owned WA gold projects. In the West Tanami region, the funds will support reverse circulation (RC)/diamond drilling at Jazz and Fremlins, aircore/RC drilling at Camel, Far SW, Hutch's and Ginger, and extend Ultrafine geochemical sampling across untested gold targets. In the Yilgarn region, the investment will enable diamond drilling of the Anderson gold anomaly, follow-up RC drilling at Ularring and initial aircore drill testing of priority gold targets at the Venus project, in addition to providing general working capital. The placement to unrelated parties will utilise Hamelin's existing placement capacity under ASX Listing Rules 7.1 and 7.1A, amounting to 23.02 million and 15.75 million new shares, respectively. Chieftain Securities and Cygnet Capital served as joint lead managers for the placement. They are set to receive a total of two million options, exercisable at $0.15 each within 24 months, subject to shareholder approval at a general meeting planned for May 2025. Hamelin's shareholder base includes gold mining companies such as Gold Fields and Vault Minerals. Hamelin managing director Peter Bewick said: 'We greatly appreciate the ongoing support from our existing shareholders and welcome new shareholders at an exciting time for the company. "Over the next few months we will be drill testing a suite of large-scale gold targets in the West Tanami and across our Yilgarn gold projects. We look forward to providing shareholders with updates on the progress of these activities and as results are received.' "Hamelin Gold to accelerate exploration at WA gold projects with $1.68m placement" was originally created and published by Mining Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
